Informazioni
Non ci sono recensioni
Punto di Riferimento
per Medici e Operatori Sanitari
per Medici e Operatori Sanitari
LIBRERIA STUDIUM
Vitiligo
Picardo, Taïeb
Editore
Springer
Anno
2010
Pagine
483
ISBN
9783540693604
160,00 €
- First highly up-to-date book showing new therapies for vitiligo
- Is lavishly illustrated, covering all aspects
- Presents an overview on the classification, pathogenesis, methods of diagnosis and treatment of vitiligo
- All therapy recommendations are based on new evidence-based guidelines
- Includes case studies with illustrations before and after the treatment, demonstrating treatment success
- Is designed for beginners in the field as well as experts
Vitiligo is one of the most common cutaneous disorders. Great numbers of affected patients suffer from the high stigmatizing impact of this disease. Up to now, clinical guidelines for the treatment of vitiligo were non-existent. In order to fill this void, this textbook defines and gives a complete overview of the disease, both regarding the classification of differential diagnosis as well as the treatment. Written by the most authoritative experts in the field, all therapy recommendations are based on new evidence-based guidelines. It includes case studies with illustrations before and after the treatment in order to demonstrate the treatment success. This textbook will be a valuable resource for all physicians who are seeing patients with this disease.
vii
Section 1: Defi ning the Disease
1.1 Historical Aspects. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Yvon Gauthier and Laila Benzekri
1.2 Clinical Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.2.1 Epidemiology, Defi nitions and Classifi cation. . . . . . . . . . . . . . . . . . 13
Alain Taïeb and Mauro Picardo
1.2.2 Histopathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Flávia Pretti Aslanian, Absalom Figueira,
Tullia Cuzzi, and Béatrice Vergier
1.3 Clinical Aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
1.3.1 Generalized Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Thierry Passeron and Jean-Paul Ortonne
1.3.2 Segmental Vitiligo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Seung-Kyung Hann, Yvon Gauthier, and Laila Benzekri
1.3.3 Vitiligo Universalis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
Prasad Kumarasinghe
1.3.4 Mucosal Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Davinder Parsad
1.3.5 Halo Nevi and Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
Thomas Jouary and Alain Taïeb
1.3.6 Hair Involvement in Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
Rafael Falabella
1.3.7 Non-Skin Melanocytes in Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
Raymond E. Boissy
Contents
viii Contents
1.3.8 Autoimmune/Infl ammatory and Other Diseases
Associated with Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
Ilse Mollet, Nanny van Geel, and Jo Lambert
1.3.9 Vitiligo and Immunodefi ciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
Khaled Ezzedine, Sébastien Lepreux, and Alain Taïeb
1.3.10 Infl ammatory Vitiligo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Khaled Ezzedine, Julien Seneschal, Ratnam Attili, and Alain Taïeb
1.3.11 Rare Inherited Diseases and Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . 107
Alain Taïeb and Fanny Morice-Picard
1.3.12 Vitiligo in Childhood . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
Juliette Mazereeuw-Hautier and Alain Taïeb
1.3.13 Late-Onset Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
Davinder Parsad and Dipankar De
1.4 Evaluation, Assessment and Scoring . . . . . . . . . . . . . . . . . . . . . . . . 127
Alain Taïeb and Mauro Picardo
1.5 Quality of Life. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135
Davinder Parsad
1.6 Natural History and Prognosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139
Davinder Parsad
1.7 Defi ning the Disease: Editor’s Synthesis . . . . . . . . . . . . . . . . . . . . . 143
Alain Taïeb and Mauro Picardo
Section 2: Understanding the Disease
2.1 Pathophysiology Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
Mauro Picardo and Alain Taïeb
2.2 Generalized Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
2.2.1 Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
Richard Spritz
2.2.2 Environmental Factors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
2.2.2.1 The Kobner’s Phenomenon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
Yvon Gauthier and Laila Benzekri
2.2.2.2 Occupational Vitiligo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175
Raymond E. Boissy
2.2.3 In Vivo Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181
Contents ix
2.2.3.1 Non-Invasive Methods for Vitiligo Evaluation. . . . . . . . . . . . . . . . . 183
Marco Ardigò, Francesca Muzio, Mauro Picardo,
and Valeria Brazzelli
2.2.3.2 Electron Microscopy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197
Yvon Gauthier
2.2.4 Animal Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205
Gisela F. Erf
2.2.5 In Vitro Approaches. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219
Muriel Cario-André and Maria Lucia Dell’Anna
2.2.6 Oxidative Stress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
Mauro Picardo and Maria Lucia Dell’Anna
2.2.7 Immune/Infl ammatory Aspects. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239
2.2.7.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 239
Alain Taïeb
2.2.7.2 The Role of Innate Immunity in Vitiligo . . . . . . . . . . . . . . . . . . . . . 240
Anna Peroni and Giampiero Girolomoni
2.2.7.3 Humoral Immunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248
E. Helen Kemp, Anthony P. Weetman,
and David J. Gawkrodger
2.2.7.4 Cell-Mediated Immunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 256
I. Caroline Le Poole and David A. Norris
2.2.8 Cytokines and Growth Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 269
Genji Imokawa and Silvia Moretti
2.2.9 Proopiomelanocortin and Related Hormones . . . . . . . . . . . . . . . . . 283
Markus Böhm
2.2.10 Other Hypotheses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 291
Mauro Picardo
2.3 Segmental Vitiligo: A Model to Understand Vitiligo? . . . . . . . . . . 295
2.3.1 Particular Clinical Characteristics of Segmental Vitiligo . . . . . . . 296
Seung-Kyung Hann
2.3.2 The Concept of Mosaicism Applied to SV . . . . . . . . . . . . . . . . . . . . 298
Alain Taïeb
2.3.3 The Neurogenic Hypothesis in Segmental Vitiligo . . . . . . . . . . . . . 302
Yvon Gauthier and Laila Benzekri
x Contents
2.3.4 Segmental Vitiligo: A Model for Understanding
the Recapitulation of Repigmentation . . . . . . . . . . . . . . . . . . . . . . . 306
Hsin-Su Yu, Cheng-Che Eric Lan, and Ching-Shuang Wu
2.4 Editor’s Synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311
Mauro Picardo and Alain Taïeb
Section 3: Therapy
3.1 Management Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 319
Alain Taïeb and Mauro Picardo
3.2 Topical Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 325
3.2.1 Topical Corticosteroids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 327
Wietze Van der Veen, Bas S. Wind, and Alain Taïeb
3.2.2 Calcineurin Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 331
N. van Geel, B. Boone, I. Mollet, and J. Lambert
3.2.3 Vitamin D Analogues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 339
Mauro Picardo
3.3 Phototherapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 343
3.3.1 PUVA and Related Treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 345
Agustin Alomar
3.3.2 UVB Total Body and Targeted Phototherapies . . . . . . . . . . . . . . . . 353
Giovanni Leone and Adrian Tanew
Microphototherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 362
Torello Lotti, Francesca Prignano, and Gionata Buggiani
3.4 Vitamins and Antioxidants: Topical and Systemic. . . . . . . . . . . . . 369
Mauro Picardo and Maria Lucia Dell’Anna
3.5 Systemic Treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375
3.5.1 Corticosteroid Minipulses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 377
Davinder Parsad and Dipankar De
3.5.2 Other Immunosuppressive Regimen . . . . . . . . . . . . . . . . . . . . . . . . 381
Markus Böhm
3.6 Empirical, Traditional, and Alternative Treatments. . . . . . . . . . . . 387
Mauro Picardo and Alain Taïeb
Contents xi
3.7 Surgical Therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 393
3.7.1 Background and Techniques . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 395
Mats J. Olsson
3.7.2 The Outcomes: Lessons About Surgical Therapy
for Vitiligo in the Past Two Decades. . . . . . . . . . . . . . . . . . . . . . . . . 409
Rafael Falabella
3.8 Combined Therapies for Vitiligo. . . . . . . . . . . . . . . . . . . . . . . . . . . . 417
Thierry Passeron and Jean-Paul Ortonne
3.9 Camoufl age . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 423
Alida de Pase and Thomas Jouary
3.10 Photoprotection Issues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431
Alessia Pacifi co, Giovanni Leone and Mauro Picardo
3.11 Depigmenting Agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439
Mauro Picardo and Maria Lucia Dell’Anna
3.12 Therapy Adapted for Age, Gender, and Specifi c Locations . . . . . 443
Alain Taïeb and Inka Nieuweboer-Krobotova
3.13 Psychological Interventions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447
Panagiota Kostopoulou and Alain Taïeb
3.14 The Patient Perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 451
Maxine E. Whitton and Alida DePase
3.15 Evidence-Based Medicine Perspective . . . . . . . . . . . . . . . . . . . . . . . 461
Jean-Paul Ortonne, Thierry Passeron, DJ Gawkrodger,
Davinder Prasad, and Somesh Gupta
3.16 Editor’s Synthesis and Perspectives . . . . . . . . . . . . . . . . . . . . . . . . . 471
Alain Taieb and Mauro Picardo
